Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies (SLA-DOM)

The diagnosis and the follow-up of the patients reached of SLA is centralized, since a few years, at the the Caribbean Reference center of the rare neurological diseases (CERCA labélisé in 2006) in Martinique and at the Unity of coverage of the neuromuscular Diseases, SLA and the rare neurological diseases (create in 2010) in Guadeloupe. Several phenotypic characteristics seemed to us to take out again data collected during the follow-up of the patients (26 in Guadeloupe, since the creation of the unity) in particular patients' high proportion of exceptionally long evolution (more than 10 years). Besides, we diagnosed several cases (10 cases in Guadeloupe since 2000) of association SLA- Parkinsonien Syndrome.

This association, considered as exceptional could establish a particular phenotypic entity which we would like to describe. We are interested also originally geographical of the patients, with the hypothesis that he could exist in the Antilles one or several geographical isolates of the disease allowing to lead a étiologique investigation in search of a possible genetic or environmental cause.

Study Overview

• Status: Recruiting
• Conditions: Amyotrophic Lateral Sclerosis
• Intervention / Treatment: Dietary supplement: Blood sample and environmental survey

Detailed Description

The amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive muscular paralysis due to degeneration of motor neurons in the primary motor cortex, corticospinal pathway, brain stem and spinal cord. The incidence is estimated at 2/100 000 per year and prevalence at approximately 4/100000.

Various clinical forms are described. The disease is fatal is 3-5 years on average.

The majority of cases are sporadic and of unknown origin but 5-10% are familial and present for 20% of them, mutations in the SOD1 (21q22.11) gene. Other genes have recently been implicated in ALS. Environmental toxic factors have been extensively researched. Beta-methylamino-L-alanine (BMAA), a neurotoxic nonprotein amino acid produced by most cyanobacteria, has been proposed to be the causative agent of the ALS-Parkinsonism Complex on the island of Guam in the Pacific Ocean.

Epidemiology and clinical features of ALS have never been studied in Caribbean countries.

The main purpose of the study will be to evaluate the incidence of ALS in Guadeloupe and Martinique.

Secondary purposes will be:

1. to evaluate the presence of specific phenotypic features;
2. to establish he prognosis of different clinical forms;
3. to study the genes implicated in ALS and quantify theexposure to BMAA.

Since 2000, the diagnosis of ALS is made in about 20 patients per year in Guadeloupe and Martinique(for a total population of 800000 inhabitants) but the incidence and the clinical presentation of ALS in the French West Indiesare unknown.

The exceptional association of ALS and parkinsonism is regularly observed in Guadeloupe. We propose to perform a prospective descriptive and longitudinal epidemiological study to determine the incidence of ALSin the French West Indies. In parallel we will study the involvement of genetic andenvironmental toxic factors as etiological factor for this disease.

Primary outcome:

- the impact of ALS in Guadeloupe and Martinique

Secondary outcomes:

• Assess the clinical characteristics (presence of phenotypic features?),
• the prognosis of different clinical forms study,
• to establish the genetic factors of the ALS and to search potential environmental factors

• Study Type: Interventional
• Enrollment (Anticipated): 70
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Chantal LERUS, Director of Clinical Research; Phone Number: (+590) 0590 93 46 86; Email: chantal.lerus@chu-guadeloupe.fr
• Study Contact Backup: Name: Valerie SOTER, Manager of Reseach; Phone Number: (+590) 0590 93 46 86; Email: valerie.soter@chu-guadeloupe.fr

Study Locations

• Guadeloupe
  • Pointe-à-Pitre, Guadeloupe, 97159
    • Recruiting
    • Hospital University Center of Pointe-à-Pitre
    • Contact: Chantal LERUS, Director of Clinical Research; Phone Number: (+590) 0590 93 46 86; Email: chantal.lerus@chu-guadeloupe.fr
    • Contact: Valerie SOTER, Manager of Reseach; Phone Number: (+590) 0590 93 46 86; Email: valerie.soter@chu-guadeloupe.fr
    • Principal Investigator: Alice DEMOLY, Neurologist
• Martinique
  • Fort-de-France, Martinique, 97261
    • Recruiting
    • Hospital University Center of Martinique
    • Contact: Chantal LERUS, Director of Clinical Research; Phone Number: (+590) 0590 93 46 86; Email: chantal.lerus@chu-guadeloupe.fr
    • Contact: Valerie SOTER, Manager of Reseach; Phone Number: (+590) 0590 93 46 86; Email: valerie.soter@chu-guadeloupe.fr
    • Principal Investigator: Remy BELLANCE, Neurologist

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient or third-party responsible for receiving information on the study and who signed informed consent ;
• Patient age over 18 years;
• Patient living in the Antilles;
• Patient with ALS or SLP (primary lateral sclerosis, pure central form of ALS).

Exclusion Criteria:

• Patient non-affiliated to the social security scheme ;
• in case of difficulty of monitoring patient, exclusion of the longitudinal study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: DIAGNOSTIC
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

OTHER: ALS's patients in Guadeloupe and Martinique; We shall determine: Impact of ALS in Guadeloupe and Martinique; Prevalence of the ALS in Guadeloupe and Martinique on the duration of the study; The distribution of ALS various phenotypes in our population of patients.; We shall collect the date of the beginning of the symptoms of the SLA, the date of diagnosis of ALS, the date of death for the same individual and the origin of the death, the weight, the size, the albumin, CRP; in order to establish the forecast of the various clinical forms, the description of the evolution of the nutritional state.; Search for transfers of genes TARDBP, VCP, SOD1 known and involved in the disease; Search for possible environmental factors

Dietary supplement: Blood sample and environmental survey; The intervention corresponds to a 10 ml of Blood sample and an environmental survey.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the impact of amyotrophic lateral sclerosis in Guadeloupe and Martinique	Number of new cases per year.	Through study completion, an average of 6 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Estimate prevalence of the ALS	Determine the total number of case of ALS diagnosed in Guadeloupe and Martinique on the duration of the study	Through study completion, an average of 6 years
Clinical criteria of SLA	General, neurological, digestive clinical examination and cardiorespiratory complete and the realization of the score " ALS funtional rating scale "	Through study completion, an average of 9 years
Study the genetic factors of the ALS	Search for transfers of genes TARDBP, VCP, SOD1: According to the genealogical data, we shall target the possible family forms to test at these patient's the various genes known and involved in the disease (transfers of the gene SOD1 (21q22.11), of the gene TARDBP (1p36.22) coding the protein TAR DNA-binding protein 43 (TDP-43) and of the gene VCP (9p13.3) coding for the protein Valosin Containing Protein). For the sporadic cases the analysis of these genes will be realized on the whole studied population. For the family cases the genetic study will be spread in the whole family.	Through study completion, an average of 9 years

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Pointe-a-Pitre
• Investigators: Study Director: Annie LANNUZEL, Professor, Neurological, Hospital University Center of Pointe-à-Pitre

Study record dates

Study Major Dates

• Study Start (ACTUAL): May 13, 2014
• Primary Completion (ANTICIPATED): May 13, 2020
• Study Completion (ANTICIPATED): May 13, 2023

Study Registration Dates

• First Submitted: November 28, 2017
• First Submitted That Met QC Criteria: December 4, 2017
• First Posted (ACTUAL): December 11, 2017

Study Record Updates

• Last Update Posted (ACTUAL): December 11, 2017
• Last Update Submitted That Met QC Criteria: December 4, 2017
• Last Verified: November 1, 2017

More Information

Terms related to this study

• Keywords: genetic; epidemiology; amyotrophic lateral sclerosis; environmental factor
• Additional Relevant MeSH Terms: Pathologic Processes; Metabolic Diseases; Central Nervous System Diseases; Nervous System Diseases; Neuromuscular Diseases; Neurodegenerative Diseases; Spinal Cord Diseases; TDP-43 Proteinopathies; Proteostasis Deficiencies; Sclerosis; Motor Neuron Disease; Amyotrophic Lateral Sclerosis
• Other Study ID Numbers: RBM-PAP-2013/55

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No